CX3CL1: A Protein Involved in Cell Signaling and Adhesion (G6376)

Target Name: CX3CL1

NCBI ID: G6376

CX3CL1

CX3CL1: A Protein Involved in Cell Signaling and Adhesion

CX3CL1, also known as CX3CL1A or CX3CL1, is a protein that is expressed in various cell types, including immune cells, endothelial cells, and epithelial cells. It is a member of the CXCR3 family, which is known for its role in cell-signaling and adhesion. One of its most well-known functions is as a chemokine, which is a protein that is able to attract and activate certain types of immune cells.

CX3CL1 is able to induce the activation and recruitment of immune cells, such as T cells and NK cells, to sites of infection or damage. This is thought to be done through its ability to interact with the immune cell's receptor, known as the CXCR1 receptor. This receptor is found on the surface of many immune cells, including T cells, and is involved in the regulation of cell signaling.

CX3CL1 is also involved in the regulation of cell adhesion and migration. This is done through its ability to interact with the Integrin receptor, which is found on the surface of many different types of cells. This receptor is involved in the regulation of cell stickiness and movement, and is thought to be involved in the development of cancer.

CX3CL1 is also involved in the regulation of inflammation. This is done through its ability to interact with the pro-inflammatory receptor, known as NF-kappa-B. This receptor is involved in the regulation of inflammation and pain, and is thought to be involved in the development of many diseases, including cancer.

Due to its involvement in these processes, CX3CL1 is a potential drug target. Researchers are currently working to develop drugs that can inhibit the activity of CX3CL1, in order to treat a variety of diseases. For example, some researchers are studying the potential of these drugs to treat cancer, by targeting the activity of CX3CL1. Other researchers are studying the potential of these drugs to treat autoimmune diseases, by targeting the activity of CX3CL1.

In addition to its potential as a drug target, CX3CL1 is also a potential biomarker. This is because its activity can be easily measured and detected in a variety of cell types. This makes it a promising tool for the study of disease mechanisms and the development of new diagnostic tests.

Overall, CX3CL1 is a protein that is involved in a variety of important cellular processes. Its activity as a chemokine, cell adhesion and migration regulator, and inflammation regulator makes it a potential drug target and biomarker. Further research is needed to fully understand its role in these processes and its potential as a therapeutic agent.

Protein Name: C-X3-C Motif Chemokine Ligand 1

Functions: Chemokine that acts as a ligand for both CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1 (PubMed:9782118, PubMed:12055230, PubMed:23125415, PubMed:9931005, PubMed:21829356). The CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis (PubMed:9024663, PubMed:9177350, PubMed:9782118, PubMed:12055230). Regulates leukocyte adhesion and migration processes at the endothelium (PubMed:9024663, PubMed:9177350). Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner (PubMed:23125415, PubMed:24789099). In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins (PubMed:23125415, PubMed:24789099). In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1 (PubMed:23125415, PubMed:24789099)

The "CX3CL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CX3CL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets